Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP known ✓ | P19971 | 20/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1682930 | 0.98 | TYMP (0.58) | TYMP | |
| Hydrochloric Acid SCHEMBL6572739 | 0.84 | TYMP (0.54) | TYMP | |
| SCHEMBL6572715 | 0.83 | TYMP (0.57) | TYMP | |
| Hydrochloric Acid SCHEMBL1691079 | 0.81 | TYMP (0.51) | TYMP | |
| Hydrochloric Acid SCHEMBL1682955 | 0.74 | TYMP (1.00) | TYMP | |
| SCHEMBL6571732 | 0.73 | TYMP (0.53) | TYMP | |
| Hydrochloric Acid SCHEMBL1691080 | 0.72 | TYMP (0.56) | TYMP | |
| SCHEMBL6571658 | 0.70 | TYMP (0.71) | TYMP | |
| SCHEMBL20599962 | 0.69 | TYMP (0.59) | TYMP | |
| SCHEMBL6060121 | 0.67 | TYMP (0.52) | TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303283-A2 | ANTI-CANCER COMBINATION THERAPY | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2011-04-06 | — | — | EP | claimed |
| US-20110065663-A1 | ANTI-CANCER COMBINATION THERAPY | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D | 2011-03-17 | — | — | US | claimed |
| US-20100240682-A1 | PHOPHYLACTIC OR THERAPEUTIC AGENT FOR INFLAMATORY DISEASE COMPRISING THYMIDINE PHOSPHORYLASE INHIBITOR AS ACTIVE INGREDIENT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2010-09-23 | — | — | US | claimed |
| EP-2204192-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR INFLAMMATORY DISEASE COMPRISING THYMIDINE PHOSPHORYLASE INHIBITOR AS ACTIVE INGREDIENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2010-07-07 | — | — | EP | claimed |
| WO-2009138507-A2 | ANTI-CANCER COMBINATION THERAPY | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2009-11-19 | — | — | WO | claimed |
| EP-0884051-B1 | CANCEROUS METASTASIS INHIBITORS CONTAINING URACIL DERIVATIVES | TAIHO PHARMACEUTICAL CO LTD (JP) | 2004-12-15 | — | — | EP | claimed |
| EP-0763529-B1 | URACIL DERIVATIVES, AND ANTITUMOR EFFECT POTENTIATOR AND ANTITUMOR AGENT CONTAINING THE SAME | TAIHO PHARMACEUTICAL CO LTD (JP) | 2003-07-23 | — | — | EP | claimed |
| US-6255314-B1 | Cancerous metastasis inhibitors containing uracil derivatives | TAIHO CHARMACEUTICAL CO., LTD. (JP) | 2001-07-03 | — | — | US | claimed |
| US-6159969-A | Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2000-12-12 | — | — | US | claimed |
| EP-0884051-A1 | CANCEROUS METASTASIS INHIBITORS CONTAINING URACIL DERIVATIVES | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1998-12-16 | — | — | EP | claimed |
| EP-0763529-A1 | URACIL DERIVATIVES, AND ANTITUMOR EFFECT POTENTIATOR AND ANTITUMOR AGENT CONTAINING THE SAME | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1997-03-19 | — | — | EP | claimed |
| WO-2018039359-A1 | METHODS FOR THE TREATMENT OF CANCER-ASSOCIATED BONE DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-03-01 | — | — | WO | disclosed |
| EP-2303283-A2 | ANTI-CANCER COMBINATION THERAPY | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2011-04-06 | — | — | EP | disclosed |
| US-20110065663-A1 | ANTI-CANCER COMBINATION THERAPY | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D | 2011-03-17 | — | — | US | disclosed |
| WO-2009138507-A2 | ANTI-CANCER COMBINATION THERAPY | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2009-11-19 | — | — | WO | disclosed |
| US-6255314-B1 | Cancerous metastasis inhibitors containing uracil derivatives | TAIHO CHARMACEUTICAL CO., LTD. (JP) | 2001-07-03 | — | — | US | disclosed |
| US-6159969-A | Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2000-12-12 | — | — | US | disclosed |
| EP-0884051-A1 | CANCEROUS METASTASIS INHIBITORS CONTAINING URACIL DERIVATIVES | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1998-12-16 | — | — | EP | disclosed |
| US-5744475-A | 4-N-HET-METHYLURACIL DERIVATIVES; THYMIDINE PHOSPHORYLASE INHIBITORS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1998-04-28 | — | — | US | disclosed |
| EP-0763529-A1 | URACIL DERIVATIVES, AND ANTITUMOR EFFECT POTENTIATOR AND ANTITUMOR AGENT CONTAINING THE SAME | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1997-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065663-A1 | ANTI-CANCER COMBINATION THERAPY | TYMP, MTAP, NTPCR | TYMP 1/4885 |
| US-20100240682-A1 | PHOPHYLACTIC OR THERAPEUTIC AGENT FOR INFLAMATORY DISEASE COMPRISING THYMIDINE PHOSPHORYLASE INHIBITOR AS ACTIVE INGREDIENT | TYMP, MTAP, PNP | TYMP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.